Dynamic monitoring of EGFR mutations in circulating tumor DNA for early detection of drug resistance in NSCLC patients on EGFR-TKI therapy Source: International Congress 2019 – Diagnostic procedures and biology of lung cancer Year: 2019
Lipid-related anti-cancer drug resistance of lung adenocarcinoma cells Source: Virtual Congress 2021 – Biology of lung cancer: preclinical and translational research Year: 2021
Potential therapeutic significance of CIK cells in gefitinib resistant NSCLC with EGFR mutations Source: Annual Congress 2011 - Progress in pathology of lung cancer Year: 2011
The correlation between p53 gene mutation and the expression of tumor drug resistance genes in lung cancer and its clinical significance Source: Annual Congress 2005 - Prognostic factors in lung cancer Year: 2005
The effect of new drug-resistance antisense gene on multidrug resistance mechanism of drug-resistant human small cell lung cancer cells Source: Eur Respir J 2007; 30: Suppl. 51, 715s Year: 2007
Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation Source: Eur Respir J 2011; 37: 624-631 Year: 2011
Relationship between a clinical drug resistance and immunohistochemical expression of P-glycoprotien, multidrug resistance protein, and p53 in small cell lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 231s Year: 2002
Survival prognosis and target therapy best response in adenocarcinoma lung cancer pts with mutation EGFR gene Source: Annual Congress 2009 - Treatment of lung cancer Year: 2009
Clone and initial identification of differentially expressed genes of human small-cell lung cancer multi-drug resistance cell line Source: Annual Congress 2007 - Biology of thoracic malignancies Year: 2007
Does acute phase protein alpha1-antitrypsin modulate apoptosis-autophagy crosstalk resulting in resistance of NSCLC cells to cancer drugs? Source: Virtual Congress 2021 – Biology of lung cancer: preclinical and translational research Year: 2021
Cyclooxygenase(COX)-2 is over-expressed in non small cell lung cancer (NSCLC) and is a potential target for treatment Source: Eur Respir J 2002; 20: Suppl. 38, 400s Year: 2002
Relationship between mutated P53 and the acquired multi-drug resistance after cisplatin selection in NCI-H460 cell line of human large cell lung cancer Source: Annual Congress 2004 - Molecular biology Year: 2004
The development of mutant P53 characterized by lung cancers contributes to their primary and acquired multi-drug resistance to chemotherapy Source: Eur Respir J 2005; 26: Suppl. 49, 457s Year: 2005
ABCG2 is determinant to SN-38 resistance in non-small cell lung cancer Source: Annual Congress 2005 - Prognostic factors in lung cancer Year: 2005
A possible role of intracellular calcium in the development of anti-cancer therapy -resistance in lung cancer cells Source: Eur Respir J 2006; 28: Suppl. 50, 853s Year: 2006
P-glycoprotein (p-gp) and lung resistance protein (lrp), as predictive factors of response to platinum-based chemotherapy for lung cancer Source: Eur Respir J 2001; 18: Suppl. 33, 231s Year: 2001
Second-line combination therapies in nonsmall cell lung cancer without known driver mutations Source: Eur Respir Rev 2015; 24: 582-593 Year: 2015
A variant in LKB1 gene can predicts the clinical outcomes of chemotherapy in patients with non-small cell lung cancer Source: International Congress 2018 – Lung cancer: new aspects in diagnosis and management Year: 2018
Can molecular markers (EGFR, ERCC1) serve as screening parameters for adjuvant chemotherapy decision in early staged non-small cell lung cancer patients? Source: Annual Congress 2010 - Recent developments of molecular pathology and functional genomics in non-neoplastic and neoplastic lung diseases Year: 2010